Key facts
- Enquyst Technologies’s last known valuation is $107.0M (May 2025).
- It has raised $11.2M; the latest was Later Stage VC ($6.0M) in May 2025.
- Notable investors include New Jersey Economic Development Authority, Eckuity, Capnor (Germany), Forepont Capital Partners, Innovation and Technology — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Enquyst Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Enquyst Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enquyst Technologies
Developer of biomanufacturing process technologies designed to reduce production costs and improve scalability for biologics. The company offers a modular, chromatography-free, and continuous manufacturing system that supports monoclonal antibody production and viral vector separation, enabling biopharmaceutical companies and contract development organizations to streamline downstream processing, minimize capital and operating expenditures, and accelerate access to high-purity biologic therapies.
- Sector
- Healthcare
- HQ
- North Brunswick, NJ, United States
- Founded
- 2017
- Employees
- 10
- Website
- enquyst.com/
- Ownership
- Privately Held (backing)
Enquyst Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enquyst Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enquyst Technologies in its N-PORT filings yet. We sweep new filings monthly.